Neuromuscular-blocking drugs: Use and misuse in the intensive care unit

Critical Care Clinics

Volumn 17, Issue 4, 2001, Pages 925-942

  Murphy, Glenn S ^a   Vender, Jeffery S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ATRACURIUM; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CISATRACURIUM; CLINDAMYCIN; CYCLOSPORIN; DANTROLENE; FUROSEMIDE; INHALATION ANESTHETIC AGENT; LAUDANOSINE; LIDOCAINE; LITHIUM; LOCAL ANESTHETIC AGENT; MAGNESIUM SULFATE; MIVACURIUM; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; PHENYTOIN; PIPECURONIUM; RANITIDINE; ROCURONIUM; THEOPHYLLINE; UNINDEXED DRUG; VECURONIUM;

ANALGESIA; CRITICAL ILLNESS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DETERMINATION; DRUG INDICATION; DRUG MEGADOSE; DRUG MISUSE; DRUG USE; EARLY DIAGNOSIS; HUMAN; HYPERTENSION; IATROGENIC DISEASE; INTENSIVE CARE; MUSCLE RELAXATION; MYOPATHY; NEUROMUSCULAR BLOCKING; NEUROPATHY; PATIENT CARE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SEDATION; SEPSIS; STEROID THERAPY; TACHYCARDIA;

EID: 0035179224     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(05)70187-1     Document Type: Article

References (66)

1. Sepsis and the systemic inflammatory response syndrome: Neuromuscular manifestations
2. Neuromuscular complications of sepsis
3. Physiology and pharmacology of neuromuscular transmission, with special reference to the possible consequences of prolonged blockade
4. Structure/action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat
5. Recovery from doxacurium infusion administered to produce immobility for more than four days in pediatric patients in the intensive care unit
6. A retrospective analysis of long-term use of nondepolarizing neuromuscular blocking agents in the intensive care unit, and guidelines for drug selection
7. Muscle proteolysis induced by a circulating peptide in patients with sepsis or trauma
8. Use of neuromuscular blocking drugs in the critically ill patient
9. Use of continuous bispectral EEG monitoring to assess depth of sedation in ICU patients
10. Changes in acetylcholine receptor number in muscle from critically ill patients receiving muscle relaxants: An investigation of the molecular mechanism of prolonged paralysis
11. Awareness during anesthesia
12. Myopathy in severe asthma
13. A possible role for glucocorticoids in denervation atrophy
14. Neuromuscular blocking agents and sedative drugs: Clinical uses and toxic effects in the critical care unit
15. The use of neuromuscular blocking drugs in intensive care practice
16. Acute type 2 myofiber atrophy in critical illness
17. Use of sedation drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. A national survey
18. Mild intraoperative hypothermia increases duration of action and spontaneous recovery of vecuronium blockade during nitrous oxide-isoflurane anesthesia in humans
19. Necrotizing myopathies in critically ill patients
20. Hyperkalaemia, cardiac arrest, suxamethonium and intensive care
21. Prolonged paralysis after long-term, high-dose infusion of pancuronium in anaesthetized cats
22. Acute quadriplegic myopathy: A complication of treatment with steroids, nondepolarizing blocking agents, or both
23. Resistance to D-tubocurarine in lower motor neuron injury is related to increased acetylcholine receptors at the neuromuscular junction
24. Tolerance and upregulation of acetylcholine receptors following chronic infusions of d-tubocurarine
25. Hyperkalaemia and cardiac arrest after the use of suxamethonium in intensive care
26. Early, routine paralysis for intracranial pressure control in severe head injury: Is it necessary?
27. Neuromuscular complications in the ICU: The spectrum of critical illness-related conditions causing muscular weakness and weaning failure
28. Long-term administration of pancuronium and pipecuronium in the intensive care unit
29. Burn injury to trunk of rat causes denervation-like responses in the gastrocnemius muscle
30. Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU
31. A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants
32. The effect of procaine on neuromuscular transmission
33. Acute myopathy of intensive care: Clinical, electromyographic, and pathologic aspects
34. Causes of neuromuscular weakness in the intensive care unit: A study of ninety-two patients
35. Critical illness myopathy and neuropathy
36. Mild hypothermia prolongs the duration of action of atracurium
37. Paralyzed with pain: The need for education
38. Adjuncts to analgesia. Sedation and neuromuscular blockade
39. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease
40. Prolonged weakness after infusion of atracurium in two intensive care patients
41. Hypothermia and pharmacokinetics and pharmacodynamics of pancuronium in the cat
42. The influence of acid-base changes on neostigmine antagonism of a pancuronium neuromuscular blockade
43. Influence of training and of inactivity on muscle strength
44. Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular blocking agents
45. The use of neuromuscular blocking drugs in the intensive care unit: A US perspective
46. Perceptions of a critically ill patient experiencing therapeutic paralysis in an ICU
47. Neuromuscular blocking agents in intensive care
48. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients
49. Complications associated with sedative and neuromuscular blocking drugs in critically ill patients
50. Recollections of ventilated patients after a stay in the intensive care unit
51. Pharmacology of muscle relaxants and their antagonists
52. Persistent paralysis in critically ill patients after long-term administration of vecuronium
53. Prolonged neuromuscular block after long term administration of vecuronium in two critically ill patients
54. Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: An executive summary
55. Prolonged paralysis and muscular weakness in critically ill patients
56. Assessing sedation during intensive care unit mechanical ventilation with the Bispectral Index and Sedation-Agitation Scale
57. Antibiotics and neuromuscular function
58. Pharmacokinetics, onset, and duration of action of org 9426 in humans: Normal versus absent renal function
59. Pancuronium bromide in the intensive care unit: A case of overdose
60. Patient recall of therapeutic paralysis in a surgical critical care unit
61. Sedatives, analgesics, and paralytics in the ICU
62. Vecuronium prevents increases in intracranial pressure during routine tracheobronchial suctioning in neurosurgical patients
63. The clinical spectrum of critical illness polyneuropathy
64. Prolonged D-tubocurarine infusion and/or immobilization cause upregulation of acetylcholine receptors and hyperkalemia to succinylcholine in rats
65. Clinical and electrophysiological findings in critical illness polyneuropathy
66. Critical illness polyneuropathy: A complication of sepsis and multiple organ failure